JP2020509050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509050A5 JP2020509050A5 JP2019547641A JP2019547641A JP2020509050A5 JP 2020509050 A5 JP2020509050 A5 JP 2020509050A5 JP 2019547641 A JP2019547641 A JP 2019547641A JP 2019547641 A JP2019547641 A JP 2019547641A JP 2020509050 A5 JP2020509050 A5 JP 2020509050A5
- Authority
- JP
- Japan
- Prior art keywords
- lineage
- epitope
- cell surface
- hematopoietic
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192752A JP7854975B6 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464975P | 2017-02-28 | 2017-02-28 | |
| US62/464,975 | 2017-02-28 | ||
| PCT/US2018/020327 WO2018160768A1 (en) | 2017-02-28 | 2018-02-28 | Compositions and methods for inhibition lineage specific proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192752A Division JP7854975B6 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509050A JP2020509050A (ja) | 2020-03-26 |
| JP2020509050A5 true JP2020509050A5 (enExample) | 2021-04-15 |
| JP7386082B2 JP7386082B2 (ja) | 2023-11-24 |
Family
ID=63370206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547641A Active JP7386082B2 (ja) | 2017-02-28 | 2018-02-28 | 系統特異的タンパク質の阻害のための組成物および方法 |
| JP2023192752A Active JP7854975B6 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192752A Active JP7854975B6 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11975029B2 (enExample) |
| EP (1) | EP3589291A4 (enExample) |
| JP (2) | JP7386082B2 (enExample) |
| KR (1) | KR102709603B1 (enExample) |
| CN (1) | CN110662554A (enExample) |
| AU (2) | AU2018229351B2 (enExample) |
| BR (1) | BR112019017751A2 (enExample) |
| CA (1) | CA3054808A1 (enExample) |
| IL (1) | IL268895B2 (enExample) |
| MX (1) | MX2019010196A (enExample) |
| RU (1) | RU2019130504A (enExample) |
| SG (1) | SG11201907870VA (enExample) |
| WO (1) | WO2018160768A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL258491B2 (en) | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| EP3676372A4 (en) * | 2017-08-28 | 2021-06-02 | The Trustees of Columbia University in the City of New York | CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33 |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| US20220127594A1 (en) * | 2019-02-13 | 2022-04-28 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020172638A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of The University Of Pennsylvania | Crispr/cas9 knock-out of cd33 in human hematopoietic stem/ progenitor cells for allogenic transplantation |
| AU2020280103A1 (en) | 2019-05-23 | 2021-12-23 | Vor Biopharma Inc. | Compositions and methods for CD33 modification |
| WO2021041977A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cd123 modification |
| AU2020338011A1 (en) | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CLL1 modification |
| US11723926B2 (en) | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| CA3155930A1 (en) * | 2019-09-27 | 2021-04-01 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| EP4048790A4 (en) * | 2019-10-22 | 2024-03-27 | Fred Hutchinson Cancer Center | BASE EDITOR-MEDIATED CD33 REDUCTION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS |
| JP7840865B2 (ja) * | 2020-03-31 | 2026-04-06 | フレッド ハッチンソン キャンサー センター | キメラ抗原受容体ターゲティングｃｄ３３ |
| EP4126248A4 (en) | 2020-03-31 | 2024-07-10 | Fred Hutchinson Cancer Center | HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES |
| EP4204565A1 (en) | 2020-08-28 | 2023-07-05 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| EP4204564A1 (en) | 2020-08-28 | 2023-07-05 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| WO2022056489A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd38 modification |
| EP4211245A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| WO2022072643A1 (en) | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| CA3199623A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| CN116744963A (zh) * | 2020-11-13 | 2023-09-12 | Vor生物制药股份有限公司 | 与表达嵌合抗原受体的经基因工程化的细胞有关的方法和组合物 |
| WO2022104090A1 (en) * | 2020-11-13 | 2022-05-19 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
| AU2021413252A1 (en) | 2020-12-31 | 2023-06-08 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| EP4380693A1 (en) | 2021-08-06 | 2024-06-12 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
| EP4430186A1 (en) | 2021-11-09 | 2024-09-18 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| IL313568A (en) | 2021-12-16 | 2024-08-01 | Universit?T Basel | Distinct cell membrane protein variants of CD117 for use in cellular therapy |
| CA3240875A1 (en) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| CN118684759A (zh) * | 2023-01-17 | 2024-09-24 | 武汉大学 | 用于治疗急性髓系白血病的成分和方法 |
| JP2026516593A (ja) | 2023-04-03 | 2026-05-26 | ウニバズィテート バーゼル | 細胞治療に使用するためのｃｄ３３の識別可能な表面タンパク質変異体 |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| CN101903403B (zh) * | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| JP6073135B2 (ja) | 2009-10-19 | 2017-02-01 | トライステム・トレイディング・（キプロス）・リミテッドＴｒｉＳｔｅｍ Ｔｒａｄｉｎｇ （Ｃｙｐｒｕｓ） Ｌｉｍｉｔｅｄ | 再プログラム化成熟成体細胞を用いる治療 |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| EP2833591A1 (en) | 2013-07-31 | 2015-02-04 | Siemens Aktiengesellschaft | Subsea data communication interface unit |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| TR201910814T4 (tr) | 2014-03-19 | 2019-08-21 | Cellectis | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. |
| ES2765710T3 (es) | 2014-04-03 | 2020-06-10 | Cellectis | Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer |
| EP3129485B2 (en) | 2014-04-09 | 2022-12-21 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| KR20160145186A (ko) | 2014-04-24 | 2016-12-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| WO2015195547A1 (en) | 2014-06-16 | 2015-12-23 | University Of Washington | Methods for controlling stem cell potential and for gene editing in stem cells |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| CN113699113A (zh) | 2014-09-16 | 2021-11-26 | 桑格摩治疗股份有限公司 | 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物 |
| KR101799975B1 (ko) | 2014-10-31 | 2017-11-21 | 에스케이씨하이테크앤마케팅(유) | 액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치 |
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CN107787367B (zh) | 2015-04-06 | 2021-10-26 | 里兰斯坦福初级大学理事会 | 用于crispr/cas介导的基因调控的化学修饰的引导rna |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| EP3288569A4 (en) | 2015-04-29 | 2018-12-19 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| IL258491B2 (en) | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP3370741B1 (en) | 2015-11-04 | 2025-10-08 | The Trustees of the University of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| WO2017091615A1 (en) | 2015-11-24 | 2017-06-01 | Cellerant Therapeutics, Inc. | Humanized anti-cll-1 antibodies |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| EP3448995A1 (en) | 2016-04-25 | 2019-03-06 | Universität Basel | Allele editing and applications thereof |
| CN118652336A (zh) | 2016-06-08 | 2024-09-17 | 普瑞赛格恩公司 | Cd33特异性嵌合抗原受体 |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US11466291B2 (en) | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
| SMT202100555T1 (it) | 2016-10-21 | 2021-11-12 | Inst Nat Sante Rech Med | Metodi per promuovere la risposta di cellule t |
| US20190365806A1 (en) | 2016-11-02 | 2019-12-05 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| CN110249052B (zh) | 2016-12-30 | 2024-04-12 | 爱迪塔斯医药公司 | 合成的指导分子、组合物和与其相关的方法 |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| KR20190140943A (ko) | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| EP3676372A4 (en) | 2017-08-28 | 2021-06-02 | The Trustees of Columbia University in the City of New York | CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33 |
| US10704938B2 (en) | 2018-01-31 | 2020-07-07 | Hydroacoustics, Inc. | Pumpjack production well including fluid sensor having 2-dimensional venturi and capacitive flow sensor |
| CN111699254A (zh) | 2018-02-08 | 2020-09-22 | 齐默尔根公司 | 使用crispr在棒状杆菌属中进行基因组编辑 |
| TWI669677B (zh) | 2018-03-07 | 2019-08-21 | 光陽工業股份有限公司 | 充電座管理方法、用於充電座管理方法的伺服器及充電座 |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| SG11202103832SA (en) | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| JP7784707B2 (ja) | 2019-01-16 | 2025-12-12 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 系統特異的抗原の阻害のための組成物および方法 |
| KR20210116526A (ko) | 2019-01-16 | 2021-09-27 | 빔 테라퓨틱스, 인크. | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| AU2020280103A1 (en) * | 2019-05-23 | 2021-12-23 | Vor Biopharma Inc. | Compositions and methods for CD33 modification |
| EA202191979A1 (ru) | 2019-05-24 | 2021-11-01 | Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк | Композиции и способы ингибирования линиеспецифических антигенов |
| AU2020338011A1 (en) | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CLL1 modification |
| WO2021041977A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cd123 modification |
-
2018
- 2018-02-28 KR KR1020197028404A patent/KR102709603B1/ko active Active
- 2018-02-28 WO PCT/US2018/020327 patent/WO2018160768A1/en not_active Ceased
- 2018-02-28 BR BR112019017751-5A patent/BR112019017751A2/pt not_active Application Discontinuation
- 2018-02-28 IL IL268895A patent/IL268895B2/en unknown
- 2018-02-28 RU RU2019130504A patent/RU2019130504A/ru unknown
- 2018-02-28 CN CN201880026602.0A patent/CN110662554A/zh active Pending
- 2018-02-28 SG SG11201907870VA patent/SG11201907870VA/en unknown
- 2018-02-28 JP JP2019547641A patent/JP7386082B2/ja active Active
- 2018-02-28 MX MX2019010196A patent/MX2019010196A/es unknown
- 2018-02-28 CA CA3054808A patent/CA3054808A1/en active Pending
- 2018-02-28 AU AU2018229351A patent/AU2018229351B2/en active Active
- 2018-02-28 EP EP18760400.4A patent/EP3589291A4/en active Pending
- 2018-02-28 US US16/489,407 patent/US11975029B2/en active Active
-
2023
- 2023-11-13 JP JP2023192752A patent/JP7854975B6/ja active Active
-
2024
- 2024-03-28 US US18/620,496 patent/US20240350550A1/en active Pending
- 2024-04-03 AU AU2024202117A patent/AU2024202117A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034217A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| Ben-Shmuel et al. | Unleashing natural killer cells in the tumor microenvironment–the next generation of immunotherapy? | |
| RU2019130504A (ru) | Композиции и способы ингибирования линиеспецифических белков | |
| KR102483822B1 (ko) | 태그된 키메라 이펙터 분자 및 그의 리셉터 | |
| TWI775768B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| RU2756247C2 (ru) | Генетически модифицированные гамма дельта т-клетки | |
| KR102095700B1 (ko) | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 | |
| Wang et al. | T-cell-based immunotherapy for osteosarcoma: challenges and opportunities | |
| JP2019536480A (ja) | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 | |
| US20220251572A1 (en) | Immune cells defective for suv39h1 | |
| EP3025719B1 (en) | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases | |
| US20190085081A1 (en) | Chimeric antigen receptor | |
| CN110494160A (zh) | T细胞受体及其针对prame阳性癌症的免疫治疗 | |
| KR20190036551A (ko) | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 | |
| JP2016520074A5 (enExample) | ||
| US20250152717A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
| US20230348854A1 (en) | Chimeric antigen receptors (cars) targeting natural killer cells | |
| JP7859985B2 (ja) | Ｃｄ３３を標的にするキメラ抗原受容体 | |
| CA3132458A1 (en) | Cd147 chimeric antigen receptors and methods of use | |
| JP2022514320A (ja) | Ｃｄ２２特異的なｔ細胞受容体およびｂ細胞悪性腫瘍の処置のための養子ｔ細胞療法 | |
| KR20200085776A (ko) | 신규한 감마 델타 t-세포 수용체 및 이의 리간드 | |
| KR20260013488A (ko) | 면역 이펙터 세포 및 이의 용도 | |
| WO2019140278A1 (en) | Immunotherapy targeting core binding factor antigens | |
| CA3250186A1 (en) | Specific binding proteins for RAS neo-antigens and their uses | |
| JP2024502170A5 (enExample) |